<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="retraction" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2023.1209909</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Retraction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Retraction: The role of LINC00284 in the development of thyroid cancer <italic>via</italic> its regulation of the microRNA-30d-5p-mediated ADAM12/Notch axis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<collab>Frontiers Editorial Office</collab>
<xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/228891"/>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="edited-by">
<p>Approved by: Tao Liu, University of New South Wales, Australia</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Frontiers Editorial Office, <email xlink:href="mailto:editorial.office@frontiersin.org">editorial.office@frontiersin.org</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>04</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>13</volume>
<elocation-id>1209909</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>04</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>04</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Frontiers Editorial Office</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Frontiers Editorial Office</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="retracted-article" xlink:href="10.3389/fonc.2021.643039" ext-link-type="doi">A Retraction of the Original Research Article <article-title>The role of LINC00284 in the development of thyroid cancer <italic>via</italic> its regulation of the microRNA-30d-5p-mediated ADAM12/Notch axis</article-title> by Hu C, Kang Z, Guo L, Qu F and Qu R (2021). <italic>Front. Oncol.</italic> 11:643039. doi:&#xa0; <object-id>10.3389/fonc.2021.643039</object-id>
</related-article>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="1"/>
<word-count count="84"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Molecular and Cellular Oncology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Following publication, concerns were raised regarding the integrity of Figures&#xa0;3L, 5A, 5B, 5C and 6A. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers&#x2019; policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.</p>
<p>This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors have not responded to correspondence regarding this retraction.</p>
</body>
</article>
